PPARA and metabolic dysfunction-associated steatotic liver disease: The improvements observed in liver and metabolic parameters in MASLD patients treated with Saroglitazar can be attributed to its dual action as a PPAR‐α/γ agonist, which targets both lipid metabolism and insulin sensitivity [27].